Soros Fund Management’s Xeris Biopharma Holdings XERS Stock Holding History

Soros Fund Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,248	Closed	-$25K	–	171
2020 Q3	$25K	Sell	4,248 -195,752	-98%	-$783K	﹤0.01%	132
2020 Q2	$532K	Buy	+200,000	New	+$696K	0.01%	132

Other funds holding XERS

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Soros Fund Management's XERS Position: Q4 2020 in Review

Soros Fund Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2020, closing a stake of 4,248 shares — an estimated $25K sold.

Soros Fund Management first reported a position in XERS in Q2 2020 and held it in 2 quarters. The position peaked at $532K in Q2 2020. 96 funds tracked by Wall St. Rank hold XERS as of Q4 2020.

Soros Fund Management reported no remaining Xeris Biopharma Holdings position as of Q4 2020 after selling out during the quarter.
Soros Fund Management sold 4,248 Xeris Biopharma Holdings shares in Q4 2020, an estimated $25K.
Soros Fund Management first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 2 quarters.
Soros Fund Management's Xeris Biopharma Holdings position peaked at $532K in Q2 2020.
96 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2020.

Based on Soros Fund Management's 13F filing for Q4 2020, filed 16 Feb 2021.